Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study) by Gavin P. Dowling, Sinead Toomey, Philip Bredin, Imelda Parker, Eibhlin Mulroe, Jacinta Marron, Olivia McLoughlin, Ausra Teiserskiene, Colm Power, Anne Marie O’Shea, Megan Greally, Patrick G. Morris, Deirdre Duke, Arnold D. K. Hill, Bryan T. Hennessy

Get full text